Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 4/20 | 0.38 |
| ▸ | JAK1 | P23458 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2738098 | 1.00 | NR1H2 (0.45) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL13438546 | 1.00 | NR1H2 (0.45) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL219779 | 1.00 | NR1H2 (0.45) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15147124 | 1.00 | NR1H2 (0.45) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15073250 | 1.00 | NR1H2 (0.45) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL18399058 | 0.86 | MEN1 (0.50) | MEN1ALDH1A1MAPTKMT2AUSP2 | |
| SCHEMBL21797138 | 0.86 | MEN1 (0.50) | MEN1ALDH1A1MAPTKMT2AUSP2 | |
| SCHEMBL17310444 | 0.86 | MEN1 (0.50) | MEN1ALDH1A1MAPTKMT2AUSP2 | |
| SCHEMBL17310442 | 0.86 | MEN1 (0.50) | MEN1ALDH1A1MAPTKMT2AUSP2 | |
| SCHEMBL17310443 | 0.86 | MEN1 (0.50) | MEN1ALDH1A1MAPTKMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360104-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4330253-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022232088-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| EP-3400228-B1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | TABOMEDEX BIOSCIENCES INC (US) | 2022-04-13 | — | — | EP | disclosed |
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2020-02-18 | — | — | US | disclosed |
| US-10428019-B2 | Chiral auxiliaries | WAVE LIFE SCIENCES LTD. (SG) | 2019-10-01 | — | — | US | disclosed |
| EP-3400228-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20180319809-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC | 2018-11-08 | — | — | US | disclosed |
| US-10059718-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2018-08-28 | — | — | US | disclosed |
| US-9957275-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820699-B2 | Cyclic amines | HOFFMANN-LA ROCHE INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| EP-1877404-A2 | NOVEL CYCLIC AMINES | F. Hoffmann-Roche AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| EP-1836163-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | Novartis AG (CH) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006114401-A2 | NOVEL CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | WO | disclosed |
| US-20060247238-A1 | Cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | US | disclosed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319809-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | NR1H2 703/4885MEN1 833/4885ALDH1A1 4091/4885 |
| US-10059718-B2 | Fused quadracyclic compounds, compositions and uses thereof | MKNK2, CYP2J2, PTGS2 | NR1H2 703/4885MEN1 833/4885ALDH1A1 4091/4885 |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | NR1H2 2641/4885MEN1 1437/4885ALDH1A1 494/4885 |
| US-10428019-B2 | Chiral auxiliaries | PCNA, POLL, TYMP | NR1H2 1772/4885MEN1 1480/4885ALDH1A1 2263/4885 |
| US-20240360104-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD4, TEAD1, TEAD2 | NR1H2 473/4885MEN1 2148/4885ALDH1A1 2261/4885 |
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | MKNK2, CYP2J2, PTGS2 | NR1H2 703/4885MEN1 833/4885ALDH1A1 4091/4885 |
| US-20060247238-A1 | Cyclic amines | F12, F11, F2 | NR1H2 1236/4885MEN1 191/4885ALDH1A1 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.